JNJ · NYSE · Pharmaceuticals
Medicines and medical devices.
Last close, Oct 1, 2026
$258.66
Adjusted for splits and dividends
Last 12 months
+39.0%
S&P 500 +14.3% over the same dates
Market value
$623B
Last close × shares outstanding
Bets against the stock: 21.2M shares sold short (0.9% of shares outstanding), -2.2% vs the previous count, 3.6 days of normal trading to buy them back. FINRA, as of Sep 15, 2026.
Insiders buying, last 90 days
None
No open-market purchases reported
Insiders selling, last 90 days
10 sales
$67.8M sold. Insiders sell for many reasons.
New federal contracts, 12 months
$2.93M
16 contracts, 71% from one agency
Revenue, fiscal 2025
$94.2B
+6.0% vs the year before
Net income, fiscal 2025
$26.8B
As reported in the annual filing
Shares outstanding
2.41B
As of Jul 17, 2026
In fiscal 2025 the company spent $5.95B buying back its own shares. Cash actually paid, from its cash-flow statement.
Emergency pharmacy carvykti for rmr
Starts Jul 31, 2026Runs until Dec 31, 2026
The Department of Veterans Affairs has already agreed to pay Johnson & Johnson $385K. The job runs until Dec 31, 2026.
4571439483!forceps plate holding
Starts Apr 10, 2026Ended Apr 15, 2026
The Defense Department has already agreed to pay Johnson & Johnson $198K. The job runs until Apr 15, 2026.
Congress tradeSits on House Energy and Commerce4 different filers disclosed JNJ within 90 days. Disclosed 16 days after the transaction; reported as an official range, not an exact amount.
4 different filers disclosed JNJ within 90 days. Disclosed 22 days after the transaction; reported as an official range, not an exact amount.
Stock since the trade -6.0% · S&P 500 -0.1% · to Oct 1Traded 49 days after resultsStock at its 52-week high
48K → 25K shares held−47% of their stake
Johnson & Johnson's WW Chair, MedTech sold $6.19M of Johnson & Johnson shares. Nobody planned it ahead of time.
Prices are daily closes from Polygon.io. Company figures come from its own SEC filings. Past moves are not a forecast. OQRO reports what was filed and never tells you what to buy or sell.
Anyone owning more than 5% must file within days. Structured filings exist since December 2024, so older stakes that were never amended may be missing.
30 certified in FY2026 Q3, vs 14 a year earlier. 30 positions in total, median offered wage $169K a year.
Labor condition applications for H-1B workers certified by the Department of Labor, counted by decision date (FY2026 Q3: Apr 1, 2026 to Jun 30, 2026, the latest quarter published). A certified application is a step before a visa petition, not a hire or a visa, and one application can cover several positions. Matched by employer ID number or name.
Last 12 months, adjusted daily closes
Adjusted close went from $186.05 on Oct 1, 2025 to $258.66 on Oct 1, 2026 (+39.0%). Disclosed trades in the last 12 months: 1 insider purchase, 29 insider sales, 7 Congress purchases, 17 Congress sales.
Short sale volume: 51.4% of the volume reported to FINRA over the last 20 trading days was marked short, above its 1-year average of 45.7%. FINRA daily files, to Oct 2, 2026.
Fails to deliver: 75K shares (about $19.4M) were not delivered on time for settlement on Aug 17, 2026. SEC fails-to-deliver data.
Short sale volume is not short interest. It counts trades marked short, including market makers selling short to fill buy orders, so it is a share of daily trading, not a count of bets against the stock. Fails to deliver have many causes, including processing delays, and are often resolved within days.
48 approvals or clearances and 46 recalls recorded by the FDA for this company and its listed subsidiaries.
From openFDA: Drugs@FDA (new applications and new uses), device 510(k) and PMA decisions, and FDA enforcement reports. Class I recalls are the most serious, Class III the least. Most recalls are started by the company itself. Labeling and manufacturing changes are not listed.
Congress trade